The purpose of this work is to determine the level of brain neurotrophic factor (BDNF, brain-derived neurotrophic factor) in the blood serum of individuals with alcohol dependence syndrome in the dynamics of alcohol withdrawal syndrome (COA), as well as to compare the results obtained with the clinical picture and the effectiveness of the therapeutic program. Material and methods. The level of BDNF in the blood serum was determined using ELISA. The dynamics of the severity of alcohol withdrawal syndrome (COA), as well as indicators characterizing the psychoemotional status and cognitive abilities of patients, were evaluated using appropriate psychometric scales. The studies were conducted on the 2nd, 8th and 21st days of abstinence. There were examined 70 patients with alcohol dependence syndrome in the dynamics of COA, who met the inclusion criteria and gave informed voluntary consent to participate in the study. Results and discussion. As the symptoms of COA decreased, there was a significant increase in the level of BDNF in the blood serum: on the 21st day of abstinence, the level of BDNF was significantly higher than the values on the 2nd and 8th day of abstinence. On the 8th day of abstinence, BDNF in the blood serum forms a direct correlation with the level of personal anxiety measured using the H scale Ch. Spielberger in the modification of Y. L. Khanin. According to multiple regression analysis on the 21st day of abstinence, BDNF can predict the severity of attraction to alcohol, established using the Pennsylvania scale of attraction to alcohol. Conclusion. Thus, the content of BDNF in the blood serum can act as an independent prognostic marker of the success of care in the treatment of COA.
- 1. Егорова, М. С., Паршикова О. В. Психометрические характеристики Короткого портретного опросника Большой пятерки (Б510) // Психологические исследования. – 2016. – Т. 9, № 45. – С. 9.
- 2. Davis, M. I. Ethanol-BDNF interactions: still more questions than answers // Pharmacol Ther. – 2008. – Vol. 118. – Р. 36–57.
- 3. Egervari, G., Siciliano C. A., Whiteley E. L., Ron D. Alcohol and the brain: from genes to circuits // Trends Neurosci. – 2021. – Vol. 44(12). – R. 1004–1015. – doi: 10.1016/j.tins.2021.09.006
- 4. Flannery, B. A., Volpicelli J. R., Pettinati H. M. Psychometric properties of the Penn alcohol craving scale // Alc. Clin. Exp. Res. – 1999. – Vol. 23, № 8. – P. 1289–1295.
- 5. Freud, T., Vostrikov A., Dwolatzky T., Punchik B., Press Y. Validation of the Russian Version of the MoCA Test as a Cognitive Screening Instrument in Cognitively Asymptomatic Older Individuals and Those With Mild Cognitive Impairment // Front Med (Lausanne). – 2020. – Vol. 13(7). – R. 447. – doi: 10.3389/fmed.2020.00447.
- 6. Kobayashi, K., Shimizu E., Hashimoto K., Mitsumori M., Koike K., Okamura N., Koizumi H., Ohgake S., Matsuzawa D., Zhang L., Nakazato M., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy // Prog Neuropsychopharmacol Biol Psychiatry. – 2005. – Vol. 29(5). – R. 658–63. – doi: 10.1016/j.pnpbp.2005.04.010.
- 7. Neufeld, M., Bunova A., Ferreira-Borges C., Bryun E., Fadeeva E., Gil A., Gornyi B., Khaltourina D., Koshkina E., Nadezhdin A., Tetenova E., Vujnovic M., Vyshinsky K, Yurasova E, Rehm J. The Alcohol Use Disorders Identification Test (AUDIT) in the Russian language – a systematic review of validation efforts and application challenges // Subst Abuse Treat Prev Policy. – 2021. – Vol. 16(1). – R. 76. – doi: 10.1186/s13011-021-00404-8.
- 8. Pittman, B., Gueorguieva R., Krupitsky E., Rudenko A. A., Flannery B. A., Krystal J. H. Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar // Alcohol Clin Exp Res. – 2007. – Vol. 31(4). – R. 612–618. – doi: 10.1111/j.1530-0277.2007. 00345.x. 9. Topiwala, A., Allan C. L., Valkanova V., Zsoldos E., Filippini N., Sexton C., Mahmood A., Fooks P., Singh-Manoux A., Mackay C. E., Kivimäki M., Ebmeier K. P. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study // BMJ. – 2017. – Vol. 357. – P. j2353. – doi: 10.1136/bmj.j2353. References 1. Egorova, M. S., Parshikova O. V. Psikhometricheskie kharakteristiki Korotkogo portretnogo oprosnika Bol’shoy pyaterki (B510) // Psikhologicheskie issledovaniya. – 2016. – T. 9, № 45. – S. 9. 2. Davis, M. I. Ethanol-BDNF interactions: still more questions than answers // Pharmacol Ther. – 2008. – Vol. 118. – Р. 36–57. 3. Egervari, G., Siciliano C. A., Whiteley E. L., Ron D. Alcohol and the brain: from genes to circuits// Trends Neurosci. – 2021. – Vol. 44(12). – R. 1004–1015. – doi: 10.1016/j.tins.2021.09.006. 4. Flannery, B. A., Volpicelli J. R., Pettinati H. M. Psychometric properties of the Penn alcohol craving scale // Alc. Clin. Exp. Res. – 1999. – Vol. 23, № 8. – P. 1289–1295. 5. Freud, T., Vostrikov A., Dwolatzky T., Punchik B., Press Y.Validation of the Russian Version of the MoCA Test as a Cognitive Screening Instrument in Cognitively Asymptomatic Older Individuals and Those With Mild Cognitive Impairment // Front Med (Lausanne). – 2020. – Vol. 13(7). – R. 447. – doi: 10.3389/fmed.2020.00447. 6. Kobayashi, K., Shimizu E., Hashimoto K., Mitsumori M., Koike K., Okamura N., Koizumi H., Ohgake S., Matsuzawa D., Zhang L., Nakazato M., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy // Prog Neuropsychopharmacol Biol Psychiatry. – 2005. – Vol. 29(5). – R. 658–63. – doi: 10.1016/j. pnpbp.2005.04.010. 7. Neufeld, M., Bunova A., Ferreira-Borges C., Bryun E., Fadeeva E., Gil A., Gornyi B., Khaltourina D., Koshkina E., Nadezhdin A., Tetenova E., Vujnovic M., Vyshinsky K., Yurasova E., Rehm J. The Alcohol Use Disorders Identification Test (AUDIT) in the Russian language –a systematic review of validation efforts and application challenges // Subst Abuse Treat Prev Policy. – 2021. – Vol. 16(1). – R. 76. – doi: 10.1186/s13011–021–00404–8. 8. Pittman, B., Gueorguieva R., Krupitsky E., Rudenko A. A., Flannery B. A., Krystal J. H. Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar // Alcohol ClinExp Res. – 2007. – Vol. 31(4). – R. 612–618. – doi: 10.1111/j.1530-0277.2007. 00345.x.
- 9. Topiwala, A., Allan C. L., Valkanova V., Zsoldos E., Filippini N., Sexton C., Mahmood A., Fooks P., Singh-Manoux A., Mackay C. E., Kivimäki M., Ebmeier K. P. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study // BMJ. – 2017. – Vol. 357. – P. j2353. – doi: 10.1136/bmj.j2353.3. Поступила 03.02.2022 г.